Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MELATONIN · 1 trial · 1 indication
Difference in the average score of sleep quality
| Arm | Type | Description |
|---|---|---|
| Novanuit® Triple Action | EXPERIMENTAL | 2 capsules of Novanuit® Triple Action once daily for 2 weeks, 30 minutes to 1 hour before bedtime. |
| Name | Type | Description |
|---|---|---|
| MELATONIN (MELATL07959) | DRUG | Pharmaceutical form:Capsule Route of administration: Oral |
Inclusion criteria : * Healthy men or women volunteers, aged from 20 to 75 years included at the moment of the inclusion visit. * Subject with Body Mass Index (BMI) between 18.5 and 29.9 kg/m² (limits included). * Good general health (based on subject interview about his/her medical history and on ...
MELATONIN is being studied for use in sleep disorders in healthy volunteers. It is an investigational small molecule in Phase 1 clinical development, evaluated for its ability to improve the quality of sleep in individuals with sleep disorders.
MELATONIN is being developed by Sanofi, a company listed on the stock exchange under the ticker SNY. The drug is currently in Phase 1 clinical development for sleep disorders.
MELATONIN is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy.
MELATONIN has one completed clinical trial, identified as NCT03514732, titled 'Study to Evaluate Improvements of the Quality of Sleep With NOVANUIT® Triple Action in Healthy Volunteers With Sleep Disorders.' The trial was conducted in Poland with 40 participants.
MELATONIN is being studied under the brand name NOVANUIT® Triple Action in the clinical trial NCT03514732. The trial evaluates the quality of sleep improvements with this product in healthy volunteers with sleep disorders.